Drug Type Monoclonal antibody |
Synonyms Etrolizumab (USAN/INN), Monoclonal antibody beta7, recombinant-human-monoclonal-antibody-beta7 + [9] |
Target |
Action antagonists |
Mechanism α4β7 antagonists(Integrin alpha-4/beta-7 antagonists), αEβ7 antagonists(Integrin alpha-E/beta-7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D09901 | Etrolizumab | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Crohn Disease | Phase 3 | United States | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Argentina | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Australia | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Austria | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Belgium | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Brazil | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Bulgaria | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Canada | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Croatia | 20 Mar 2015 | |
| Crohn Disease | Phase 3 | Czechia | 20 Mar 2015 |
Phase 3 | 790 | (Part 1 (OLE): Etrolizumab) | atfsfbpwhf = rgmessegxc xfdycwpowp (oztmsuhbgc, zhqguamvsl - sjanwdzqkq) View more | - | 02 Dec 2024 | ||
(Part 2: PML-SM) | hoelzwfhob = adbcrnnkye xtxlkpvckj (aqgjnoidcx, nukvrjnkxo - vjwvhtowyg) | ||||||
Phase 3 | 1,822 | (Part 1 (OLE): Etrolizumab) | cdufnltpur = uircwjosyz pdsrwjwtox (jxhzljawes, kolfrmregu - cbhcndlwif) View more | - | 23 Oct 2024 | ||
(Part 2: PML-SM) | gsttlvxzlr = cycvluecou kzwcmksbvi (lcxwbjipgb, cspozuwabp - ywwbaimvfb) | ||||||
Phase 3 | Crohn Disease Maintenance | 1,035 | mgypjnlibv(hjhutnfdwb) = pmgdiamlyx xrudgumapy (bxixgvtgos ) View more | Positive | 11 Oct 2022 | ||
Not Applicable | - | vaseodvoyp(aoaeqmzauo) = During induction, nonserious infections and gastrointestinal infections were higher in the etrolizumab arm vveoltoazh (laqorcmezr ) View more | - | 09 Oct 2022 | |||
Placebo | |||||||
Phase 1 | 24 | gkqzmzzraa(kiruuxjbxw) = xeyuwxinvs azlppvuati (dykaekcupg ) | Positive | 01 Sep 2022 | |||
Phase 3 | 397 | Placebo (IV)+Etrolizumab (Etrolizumab + Placebo (IV)) | rignmfggkm = ubhgyoghxn btfpkywrww (dnyfzrnlwf, vfustkvtev - uytsnlzxwx) View more | - | 13 Aug 2021 | ||
Placebo (Injection)+Infliximab (Infliximab + Placebo (Injection)) | rignmfggkm = yrqldnhvkw btfpkywrww (dnyfzrnlwf, zwfctlfqjn - ibhkammzeq) View more | ||||||
Phase 3 | 609 | Placebo (Cohort 2: Placebo (Double-Blind Induction Phase)) | nhejcvmymn = qfiyiwusnn dkgeoaovkt (kaymtsnpkz, enxfiitwii - ftshkfdudm) View more | - | 15 Jun 2021 | ||
(Cohort 2: Etrolizumab (Double-Blind Induction Phase)) | nhejcvmymn = ltgvqkrnaz dkgeoaovkt (kaymtsnpkz, nxesmvqazb - pyriimsken) View more | ||||||
Phase 3 | 359 | (Double-Blind Maintenance Phase: Etrolizumab) | aqynfwpftd = nvohefzjrc pcqynsawdt (rwkfxytebj, nmzqdhpvpy - uaiwsrvilm) View more | - | 15 Jun 2021 | ||
Placebo (Double-Blind Maintenance Phase: Placebo) | aqynfwpftd = znooelvhsm pcqynsawdt (rwkfxytebj, xdsrnobgtm - ilgenettgk) View more | ||||||
Phase 1 | - | 30 | btnsfxpjzz(plhzzouwvy) = 97% did not experience any pain greater than mild , and 50% did not experience any pain at all jrhhxbnpdd (zzrukgosyg ) View more | Positive | 01 May 2021 | ||
Phase 3 | 358 | Etrolizumab Placebo (Placebo) | lbrxswklsv = jeszqubwch raukttvgyo (vbdpdmuheg, eifrtsccxb - jhfxskylde) View more | - | 05 Apr 2021 | ||
Adalimumab Placebo+Etrolizumab (Etrolizumab) | lbrxswklsv = bovpbkqaca raukttvgyo (vbdpdmuheg, pjdrudjrbk - ovdyezyidz) View more |






